Introduction
============

The extents to which evolutionary changes have affected drug side effects among human targets remain unanswered till date. The present study intends to elucidate the grounds of unwanted toxic side effects in drug targets. A handful databases ([@evw301-B36]; [@evw301-B32]; [@evw301-B65]) for human proteome are of immense importance in this regard. Based on one of such databases (SIDER 2 of [@evw301-B36]\]) with actual experimental drug adverse data, [@evw301-B57]) worked on drug target proteins from a network perspective to explore the biological factors leveraging drug side effects in human. They ([@evw301-B57]) discovered that protein essentiality and centrality largely drive side effects of the reported drugs. Focusing on human essential targets, a recent study ([@evw301-B39]) has highlighted the influence of low affinity binding to "off-target" proteins as a potential cause of drug side effect(s). Binding to multiple targets could be another plausible reason of producing drug side effects in human ([@evw301-B58]).

Earlier, we have ([@evw301-B4]) emphasized that interactome network perturbation (drug-induced perturbation) strongly influences target drug side effects. In 2015, [@evw301-B48] found that drug side effect associated targets (SET) are better spreaders of network perturbations than nonside effect associated targets (NSET). Using two different interactome network perturbation models (edgetic perturbation model and drug-induced perturbation model), we have previously established that proteins prone to network perturbations are conserved in nature. All the aforementioned studies stress on the fact that evolutionary rates should vary between SET and NSET proteins. Therefore, in the present study, we want to identify various factors responsible for between groups (SET vs. NSET) evolutionary rate variation. A wide range of publications have already disentangled determinants of protein evolutionary rates in terms of nonsynonymous amino acid changing substitution rates (*d*N) and/or using the ratio of nonsynonymous to synonymous substitution rates (*d*N/*d*S) ([@evw301-B27]; [@evw301-B20]; [@evw301-B3]; [@evw301-B17]; [@evw301-B45]; [@evw301-B7]; [@evw301-B61]; [@evw301-B5]; [@evw301-B46]; [@evw301-B63]). A number of determinants are yet to be identified to explain total variability of protein evolutionary rates. In this perspective, another objective of our present study is to find out some novel biological attributes which we can use along with previously known evolutionary rate determinants to increase the prediction accuracy of side/non side effect associated proteins in human.

Using high-coverage genome sequence data from thirteen vertebrate species (including human, mouse, cow etc.) to evaluate the consistency of *d*N and *d*S estimates using eight commonly-used methods, [@evw301-B54] has established that all the methods yielded a nearly uniform result when estimating *d*N, but not *d*S (or *d*N/*d*S). Along with [@evw301-B54], a couple of other researchers used *d*N rather than *d*N/*d*S to compute protein evolutionary rates efficiently ([@evw301-B3]; [@evw301-B16]; [@evw301-B62]; [@evw301-B54]). Hence, in this article, we emphasized on commonly used human--mouse orthologous pair ([@evw301-B38]; [@evw301-B22]; [@evw301-B21]) to define fast evolving and slow evolving protein coding genes in SET and NSET groups on the basis of their *d*N data. Using the druggable subset (drug targeted proteins) of human genome, our study demonstrates that NSET proteins evolve faster than SET proteins, mainly within noncomplex forming group. The trend of our result does not change after controlling two major determinants of protein evolutionary rates---gene expression level and tissue expression breadth ([@evw301-B16], [@evw301-B17]; [@evw301-B45]; [@evw301-B7]; [@evw301-B47]; [@evw301-B63]). Although, target essentiality (the target protein is essential in nature) is claimed to play lead role in drug side effects (Wang et al. [@evw301-B57], [@evw301-B58]; [@evw301-B39]), we observed that the variation in evolutionary rates between SET and NSET proteins does not solely depend on target essentiality. We also used three druggability measures of targets: (i) total druggability, essential druggability, and killer druggability to explain the rate discrepancy of SET vs. NSET proteins. Among the three factors, killer druggability can partially explain the conservation of comparatively recently emerged SET proteins over older NSET proteins. In the context of protein evolution, our study establishes relationship between protein age, killer druggability, protein multifunctionality, and subcellular localization to explain the variation of evolutionary rates between the SET and NSET proteins. We observed that recently emerged SET proteins are conserved if they are membrane localized, more multifunctional, have higher killer druggability and elevated transmembrane helix content. Finally, Support Vector Machine (SVM) ([@evw301-B13]) approach was adopted to predict SET/NSET proteins considering all the evolutionary rate attributes (genomic, structural, and functional) those differ significantly between the SET and NSET proteins. Our machine learning approach can predict SET/NSET proteins to a high degree of accuracy (∼86%) with 94% precision level.

Materials and Methods
=====================

Collection of Protein Evolutionary Rate Data of Human SET and NSET Proteins
---------------------------------------------------------------------------

DrugBank v.4.3 ([@evw301-B37]) was used to retrieve a catalogue of total 2426 human drug targets and drug related information. We chose SIDER v.2 (<http://sideeffects.embl.de/>) database to identify drugs with 996 experimental side effect information ([@evw301-B36]; [@evw301-B65]). For a target protein, more than one drug may have association to side effect(s). We, therefore, considered a protein as side effect associated (SET) if its target drug(s) have at least one known side effect. Nonside effect associated proteins (NSET) are those whose drug targets are not associated with any side effect. BioMart interface of Ensembl v.82 ([@evw301-B19]) was utilized to obtain evolutionary rate (*d*N) data using human--mouse orthologous pairs with *d*S \< 3 ([@evw301-B51]; [@evw301-B4]; [@evw301-B1]). However, proteins with *d*S = 0 were not considered for this study (although the result remained unchanged when we considered them). The strength of selection was inferred based on the value of *d*N/*d*S ([@evw301-B17]; [@evw301-B45]; [@evw301-B7]; [@evw301-B54]; [@evw301-B63]). Mapping of those evolutionary rate data to SET and NSET proteins finally yielded 388 SET and 1488 NSET proteins ([supplementary table S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) with accessible *d*N (and *d*N/*d*S) data for further analyses.

Acquiring Essential Proteins and Computing Target Essential Druggability
------------------------------------------------------------------------

Target essentiality data for 2472 human proteins were obtained from the study of [@evw301-B21]. After matching these essential proteins with our data set, we finally attained target essentiality information of 120 SET and 361 NSET proteins.

Considering all 2472 human essential proteins, we first catalogued the drugs that targets essential proteins using DrugBank v.4.3 ([@evw301-B37]) data. Next, we counted the number of such drugs against each protein target of our data set to get the essential druggability of that target. By this way, we got essential druggability of 1382 proteins out of total 1876 proteins.

Estimation of Target Killer Druggability
----------------------------------------

To estimate killer druggability of a target protein, we listed the drugs for which killing/toxic side effect(s) currently exist in SIDER2 database ([@evw301-B36]). [@evw301-B65] considered death, sudden death, sudden cardiac death, cardiac death, cancer, hemorrhagic strokes, heart failure, and congestive heart failure as killing side effects. However, we considered death, sudden death, cancer, metastasis, myocardial infarction, heart failure, congestive heart failure, coma, completed suicide, stroke, and cardiac arrest as potentially toxic/killing side effects for our study. Next, we counted the number of drug(s) exhibiting killing side effects against each protein target to assign the killer druggability of the target. It is a property of SET proteins and we found the killer druggability of 215 (out of total 388) SET proteins for our investigation.

Retrieval and Analyses of Protein Complex Data
----------------------------------------------

CORUM database (<http://mips.helmholtz-muenchen.de/genre/proj/corum/>) was browsed to collect human protein complex assembly data ([@evw301-B50]). The number of complexes in which a target protein participates represents the complex number of that target ([@evw301-B11]). Thus, we perceived 385 complex forming proteins for further investigation.

To reconfirm our result, we further considered large protein complexes (size ≥ 5), since, very small protein complexes of CORUM could produce high hit rate fluctuations ([@evw301-B6]). Following this method, protein complex data for SET/NSET proteins get reduced from 385 to 178.

Estimation of Gene Expression Level and Tissue Expression Breadth
-----------------------------------------------------------------

We fetched <http://genes.mit.edu/burgelab/mrna-seq/> to retrieve human mRNA-seq data to evaluate gene expression levels ([@evw301-B55]). Following [@evw301-B30], we call a gene is expressed in a tissue if its expression value is greater than M + 2 × MAD, where M and MAD are determined by M = median(*x*); and *x* indicates the average expression values for the corresponding gene among all tissues. For each gene, we counted the number of expressed tissues to indicate its tissue expression breadth ([@evw301-B4]). To represent the expression level of a gene, we took the average expression value in the tissues where it is found to be expressed ([@evw301-B4]). By this way, we obtained expression data of total 1411 genes of our data set.

Dating Protein Age
------------------

Two different approaches were taken to quantify the phylogenetic emergence of a protein. As a first measure, we collected the list of human gene encoded proteins along with their phylostrata of origin from the [supplementary data](#sup1){ref-type="supplementary-material"} given by Domazet-Lošo and Tautz (2008). We considered a protein as "old" if it falls in ps1 or ps2 (before fungi and up to eukaryotes) group and as "new" if it belongs to any other ps group ([@evw301-B15]; [@evw301-B41]). We then mapped the age data to our data set of SET/NSET proteins which finally provided 365 "new" and 1459 "old" proteins for further analyses. As an alternative to the first method (which provides categorical age information), we estimated the evolutionary origin of our proteins of interest (in Ma: million years ago) using a phylogenetic approach implemented by ProteinHistorian tool ([@evw301-B8]). By this way, we obtained numerical age data of 1836 proteins.

Determining Pleiotropic Index of a Protein
------------------------------------------

We contemplated on Gene Ontology (GO) annotation for the "biological process" from Ensembl Genome Browser v.82 ([@evw301-B25]; [@evw301-B10]; [@evw301-B19]) to calculate the multifunctionality/pleiotropic index of a protein.

Analyzing Protein Subcellular Localization
------------------------------------------

Even though a couple of databases are available to predict subcellular localization of a protein, we deliberately used the data provided by [@evw301-B58]) to identify the subcellular localization of proteins of our data set. Following this method, we spotted the subcellular localizations of 1004 SET/NSET proteins.

However, to predict the transmembrane helices of a protein, we relied on hidden Markov model based TMHMM v.2.0 Server (<http://www.cbs.dtu.dk/services/TMHMM/>), the best performing transmembrane prediction program ([@evw301-B29]).

Statistical Analyses
--------------------

All statistical analyses were done with the help of SPSS v.13. We considered nonparametric Spearman rank correlation coefficient and two-tailed Mann--Whitney U test (MWT) to calculate correlation and difference between two data sets, respectively. To create randomized data set for performing simulation study, we used R package v. 2.13.1 (<http://www.r-project.org>). For randomization, if n1 and n2 be the sample sizes respectively (n1 \> n2); we drew n2 points from the first sample of size n1 at random to compute the mean of each subset ([@evw301-B42]). We did n2 times of such simulations. Finally, we used R v 2.13.1 package to compare the mean of two groups ([@evw301-B42]; [@evw301-B26]). The results were considered to be statistically significant if the *P* value is less than 0.05.

Implementation of Support Vector Machine
----------------------------------------

The SVM algorithm implemented in the open access LIBSVM v.2.84 package ([http://www.csie.ntu.edu.tw/∼cjlin/libsvm/](http://www.csie.ntu.edu.tw/&sim;cjlin/libsvm/)) ([@evw301-B13]) was adopted to perform prediction of SET/NSET proteins using different evolutionary rate attributes. In our data set of 1876 proteins, 388 SET proteins were classified as positives and rest of the 1488 NSET proteins was treated as negative cases. Using "subset.py" function of LIBSVM ([@evw301-B13]), 70% of the total data set was randomly chosen as the training data set and the remaining 30% was used as test set. All the attributes in the training and test data sets were scaled in the range of −1 to 1. For our study, we considered most widely used C-SVC type SVM and Radial Basis Function (RBF) kernel for better performance of our model ([@evw301-B14]). The penalty parameter C and the RBF kernel parameter g were optimized using grid search, a built in function of LIBSVM ([@evw301-B13]). In addition to 5-fold cross-validation, we checked the average performance of our model on 10 different randomly generated training and test sets.

Performance Assessment
----------------------

Considering TP, FP, TN, and FN as the number of true positives, false positives, true negatives and false negatives respectively; we estimated the prediction accuracy $\left\lbrack \frac{(TP + TN)}{(TP + FN + TN + FP)} \times 100 \right\rbrack$ of our model ([@evw301-B14]; [@evw301-B35]). In addition, we relied on a balanced measure "Matthews correlation coefficient (MCC)" during cross-validation, as the positive to negative case ratio was not one ([@evw301-B14]). The MCC value was determined using the following formula:$$MCC = \frac{\lbrack(TP \times TN) - (FP \times FN)\rbrack}{\sqrt{\lbrack(TP + FP) \times (TP + FN) \times (TN + FP) \times (TN + FN)\rbrack}}$$Where, the values +1, 0, and −1 signify a perfect, a random and an inverse prediction, respectively ([@evw301-B14]). We also determined sensitivity or recall $\left\lbrack \frac{TP}{(TP + FN)} \times 100 \right\rbrack$, specificity $\left\lbrack \frac{TN}{(TN + FP)} \times 100 \right\rbrack$, positive predictive value (PPV) or precision $\left\lbrack \frac{TP}{(TP + FP)} \times 100 \right\rbrack$, negative predictive value (NPV) $\left\lbrack \frac{TN}{(TN + FN)} \times 100 \right\rbrack$, and F-measure $\left\lbrack \frac{2 \times \text{Precision} \times \text{Sensitivity}}{(\text{Precision} + \text{Sensititvity})} \right\rbrack$ to evaluate the prediction performance of our model ([@evw301-B14]; [@evw301-B35]).

Results
=======

Side Effect Associated Drug Targets Are Conserved and Exhibit Higher Druggability
---------------------------------------------------------------------------------

In this study, we collected evolutionary rates (*d*N) data from public resources for the druggable subset of human SET and NSET proteins (*n *= 1876). We observed that SET proteins evolve slower than the NSET proteins (average *d*N~SET ~= 0.062, average *d*N~NSET~ = 0.083, *P*~MWT~ = 2.81 × 10^−5^). Similar trend was observed using *d*N/*d*S data (average *d*N/*d*S~SET ~= 0.092, average *d*N/*d*S~NSET~ = 0.126, *P*~MWT~ = 2.08 × 10^−6^). Interestingly, we did not find any difference in *d*S between SET and NSET proteins (average *d*S~SET ~= 0.676, average *d*S~NSET~ = 0.669, *P*~MWT~ = 3.65 × 10^−1^). This analysis suggests that the difference in *d*N/*d*S value between NSET and SET proteins mainly depends upon the difference in *d*N. To assess that the significance is not due to the sample size difference of the proteins of our interest, we performed nonparametric test with randomized data set of SET and NSET proteins (10,000 simulated replicates). Thereby, a significant difference (Wilcoxon rank sum test: *P* \< 2.20 ×10^−16^) in *d*N between SET and NSET strengthens the fact that our observation is free from sample size bias.

We observed an inverse correlation between total druggability (total number of drugs/target) and protein evolutionary rates (~Number\ of\ drugs/target~ ρ ^*d*N^ = −0.060, *P* = 9.00 × 10^−3^, *n* = 1876) which is in agreement with the earlier observation by [@evw301-B58]). To understand the evolutionary rate heterogeneity between human SET and NSET proteins, we pooled all the proteins into two bins according to their target drug number(s) (bin 1 \[number: 1--3\]: Low, bin 2 \[number ≥4\]: High). Interestingly, we found that the difference in *d*N between SET and NSET proteins exists only in bin 2 ([fig. 1](#evw301-F1){ref-type="fig"}), whereas the total druggability differs between SET and NSET proteins in both bin 1 (*P*~MWT~ = 1.39 × 10^−8^) and bin 2 (*P*~MWT~ = 5.58 × 10^−16^). Similar result was obtained using *d*N/*d*S (data not shown). This study affirms that total druggability may not be a crucial factor for obtaining evolutionary rate heterogeneity between human SET and NSET proteins.F[ig]{.smallcaps}. 1.---The relationships between protein evolutionary rates (*d*N) and target drug numbers of human SET vs. NSET proteins in different bins. *P*~MWT~ \< 0.05 denotes significant difference between groups.

Recently, [@evw301-B65] have claimed that 51% of FDA approved drugs have higher killing index, which usually denotes the potentiality of a drug having harmful side effects. In our analysis, we computed the number of drugs exhibiting killing side effects for each target protein and termed them as "killer druggability" of that target protein. When we correlated *d*N and the killer druggability of proteins, killer druggability has been found to have only a weak but significant negative correlation with protein evolutionary rates (Number of killer drugs/target ρ ^*d*N^ = −0.085, *P* = 2.16 × 10^−4^, *n* = 1876). This observation suggests that killer druggability may influence evolutionary rates of SET/NSET proteins. Based on protein evolutionary rates, equally populated bins (i.e., having the identical number of proteins in each of the two bins: bin 1 \[rate: 0.0006--0.0576; slow evolving\], bin 2 \[rate: 0.0576--0.5762; fast evolving\]) were constructed to better understand the distribution pattern of killer druggable proteins (proteins with killer druggability \> 0). The pattern is found to be consistent with our correlative study since slowly evolving group (bin 1) contains more proteins (58.60%) with higher killer druggability (killer druggability \> 0) than that of other proteins (48.89%) with killer druggability (killer druggability = 0) (Two sided Fisher's exact test: *P = *4.10 × 10^−2^). To comprehend the relative influences of total druggability and killer druggability on the rates of molecular evolution, we performed a linear regression analysis considering *d*N as dependent variable and total druggability, killer druggability as independent variables. We observed that killer druggability is a better predictor of protein evolutionary rates (*F *= 6.979, *P *= 1.00 × 10^−3^) than total druggability (β ~total\ druggability/target~ = −0.021, *P* = 5.26 × 10^−1^; β ~killer\ druggability/target~ = −0.070, *P* = 3.40 × 10^−2^).

Target Essentiality and Target Essential Druggability Are Not Sole Determinants of SET/NSET Protein Evolutionary Rates
----------------------------------------------------------------------------------------------------------------------

It was observed that essential genes evolved slowly than nonessential genes ([@evw301-B34]; [@evw301-B10]; [@evw301-B63]) and essential druggable targets were shown to have strong affinities towards drug side-effects ([@evw301-B39]). We mapped human essential genes \[provided by [@evw301-B21]\] to our data set and found that essential proteins evolve slower than nonessential proteins (average *d*N~Essential\ proteins\ \[*n *=* *481\] ~= 0.059, average *d*N~Nonessential\ proteins\ \[*n *=1395\]~ = 0.085, *P*~MWT~ = 4.84 × 10^−16^). This finding led us to presume that the conservation of SET proteins over the NSET group may largely attributable to their difference in essential protein contents. Despite the fact that the proportions of essential proteins are significantly higher in SET (30.93%; 120/388) compared to the NSET proteins (24.26%; 361/1488) (SET vs. NSET: *Z* score = 2.679, *P *= 7.40 × 10^−3^), no significant difference in the rate of protein evolution was detected between SET and NSET proteins within the essential gene set (average *d*N~SET ~= 0.055, average *d*N~NSET~ = 0.061, *P*~MWT~ = 7.74 × 10^−1^). From this study, we infer that the difference in rate of evolution between SET and NSET proteins is independent of target essentiality.

In other words, the number of essential proteins that bind to a drug is a key predictor of drug side-effects ([@evw301-B57]; [@evw301-B39]). To investigate, we introduced a new term "essential druggability" of a target protein which actually denotes the number of drug(s) having one or more essential partner(s) for each target protein (irrespective of the essential/nonessential nature of the target). We hypothesize that increasing essential druggability of a target will intensify its sequence conservation rate and indeed we observed the same trend (Number of drugs that binds to essential proteins/target ρ ^*d*N^ = −0.147, *P* = 1.00 × 10^−6^, *n* = 1382). We also found that essential druggability differs between SET and NSET protein targets (average essential druggability~SET\ \[*n *=* *360\] ~= 9.328, average essential druggability~NSET\ \[*n *=* *1022\]~ = 2.208, *P*~MWT~ = 1.21 × 10^−62^). We thus infer that essential druggability could be a potential evolutionary rate determinant. To better understand, proteins are pooled into a number of bins by means of their essential druggability (bin 1 \[number: 1--2\]: Low, bin 2 \[number: 3--4\]: Medium, bin 3 \[number ≥5\]: High). Thereby, we found that the difference in *d*N does not exist between SET and NSET proteins in any of the three bins (*P*~MWT~: bin 1 = 2.87 × 10^−1^, bin 2 = 2.08 × 10^−1^, bin 3 = 4.16 × 10^−1^) while target druggability differs in bin 1 and bin 3 (*P*~MWT~: bin 1 = 2.00 × 10^−3^, bin 2 = 8.90 × 10^−2^, bin 3 = 2.42 × 10^−5^). The result does not change using *d*N/*d*S data (data not shown). All these analyses indicate that essential druggability may not be a sole crucial factor for obtaining evolutionary rate heterogeneity between SET and NSET proteins.

Noncomplex Forming Ability Plays Key Role in Evolutionary Rate Disparity between SET and NSET Proteins
------------------------------------------------------------------------------------------------------

Protein complexes where two or more proteins integrate to carry out and regulate a variety of cellular functions and essential genes are more likely to be components of the protein complexes ([@evw301-B56]; [@evw301-B10]; [@evw301-B59]). Such complex forming proteins endure strong selective pressure due to their functional constraints ([@evw301-B52]; [@evw301-B40]; [@evw301-B11]). Even though, complex forming proteins are found to be slow evolving than noncomplex forming protein (average *d*N~complex\ forming\ \[*n *=385\] ~= 0.063, average *d*N~noncomplex\ forming\ \[*n *=1491\]~ = 0.083, *P*~MWT~ = 7.45 × 10^−13^), we did not find any difference in protein complex number (number of complexes a protein belongs to) between SET and NSET protein sets (average complex number~SET\ \[*n *=* *388\] ~= 0.771, average complex number~NSET\ \[*n *=* *1488\] ~= 0.795, *P*~MWT~ = 4.95 × 10^−1^). We, thus, infer that complex number may not be an evolutionary rate determinant of SET and NSET proteins.

We splitted our data set into (i) complex forming (complex number \> 0) and (ii) noncomplex forming (complex number = 0) groups. Subsequent analysis demonstrates that SET and NSET proteins are under equal selective constraint (*d*N/*d*S) within complex forming group ([fig. 2*a*](#evw301-F2){ref-type="fig"}) plausibly due to their comparable functional utility. However, the difference in *d*N (within complex difference: *P*~MWT~ = 5.15 × 10^−1^; within noncomplex difference: *P*~MWT~ = 9.11 × 10^−6^) and *d*N/*d*S between SET and NSET proteins persist in noncomplex forming group ([fig. 2*a*](#evw301-F2){ref-type="fig"}), where almost equal proportions of SET (80.67%; 313/388) and NSET (79.17%; 1178/1488) proteins are present (SET vs. NSET: *Z* score = 0.653, *P *= 5.14 × 10^−1^). From this analysis, we conclude that the observed difference in evolutionary rates between SET and NSET proteins may be guided by protein noncomplex forming ability irrespective of their sample size bias.F[ig]{.smallcaps}. 2.---The impact of complex forming ability on *d*N/*d*S of SET and NSET proteins. The bar graphs demonstrate the difference in the distribution of *d*N/*d*S between SET and NSET proteins in complex/noncomplex forming groups considering (*a*) all protein complexes (*b*) large protein complexes (size ≥ 5) of CORUM database. *P*~MWT~ \< 0.05 between groups was used to represent a statistically significant difference. Error bars signify 95% confidence interval.

A recent article has emphasized that some protein complexes those are very small in size may prompt high hit rate variations ([@evw301-B6]). To reconfirm our result, we considered protein complexes with size ≥ 5 ([@evw301-B6]). Further analyses revealed an identical trend i.e. the *d*N (within complex difference: *P*~MWT~ = 6.11 × 10^−1^; within noncomplex difference: *P*~MWT~ = 6.83 × 10^−7^) or *d*N/*d*S difference between SET and NSET proteins remains insignificant only within the complex forming group ([fig. 2*b*](#evw301-F2){ref-type="fig"}). This study affirms that noncomplex forming ability acts as an important evolutionary rate determinant of SET and NSET proteins, independent of protein complex sizes.

Gene Expression Level and Tissue Expression Breadth Are Inadequate to Explain Evolutionary Rate Variation between SET and NSET Proteins
---------------------------------------------------------------------------------------------------------------------------------------

Proteins belonging to multiple complexes (higher protein complex association number) are comparatively highly expressed than proteins those have subunits of fewer protein complexes or those do not form any complex ([@evw301-B10]). In addition, gene expression level is known as primary determinant of evolutionary rate because highly expressed genes reduce mistranslation induced misfolding cost by experiencing higher selective constraints ([@evw301-B16], [@evw301-B17]; [@evw301-B45]; [@evw301-B62]; [@evw301-B63]). Therefore, it is necessary to determine the influence of gene expression levels on the rates of evolution of SET/NSET proteins to draw any further inference. We did not find any significant correlation between gene expression level and *d*N; although a weak negative correlation exists between gene expression level and *d*N/*d*S (~Expression\ level~ ρ ^*d*N ^= −0.024, *P* = 3.60 × 10^−1^, *n* = 1411; ~Expression\ level~ ρ^*d*N/*d*S ^= −0.077, *P* = 4.00 × 10^−3^, *n* = 1411). In contrast, we obtained a lower gene expression level in SET group of genes compared to the NSET group (average gene expression level~SET\ \[*n *=* *385\] ~= 48.740, average gene expression level~NSET\ \[*n *=* *1491\]~ = 92.624, *P*~MWT~ = 6.22 × 10^−5^). We also estimated expression levels of SET and NSET genes separately within complex and noncomplex forming groups. SET genes are found to be lowly expressed than NSET genes, whereas difference in *d*N or *d*N/*d*S between SET and NSET does not exist (*complex forming group*: average gene expression level~SET\ \[*n *=* *55\]\ vs*.*\ NSET\ \[*n *=* *268\]~ = 44.411 vs. 82.126, *P*~MWT~ = 3.00 × 10^−3^; *noncomplex forming group*: average gene expression level ~SET\ \[*n *=* *194\]\ vs*.*\ NSET\ \[*n *=* *894\] ~= 49.967 vs. 95.771, *P*~MWT~ = 3.00 × 10^−3^). This finding highlights the fact that gene expression level does not have any influence in explain the evolutionary rate variations between SET and NSET group.

It has been argued that tissue expression breadth has more influence on protein evolutionary rate than gene expression level and such tissue-specific genes evolve faster than broadly expressed housekeeping genes ([@evw301-B18]; [@evw301-B64]; [@evw301-B47]). In this context, it is expected that conserved SET proteins are comparatively broadly expressed than the NSET proteins. Surprisingly, we noticed a lower tissue expression breadth of SET group of proteins (average expression breadth ≈ 8, *n* = 249) compared to NSET (average expression breadth ≈ 12, *n* = 1162, and *P*~MWT~ for SET vs. NSET tissue expression breadth = 1.80 × 10^−12^) proteins, implies that side effect associated genes tend to be expressed in limited number of tissues in spite of their lower evolutionary rates. Similar trends were observed in complex (SET vs. NSET: *P*~MWT~ = 8.48 × 10^−5^) and noncomplex (SET vs. NSET: *P*~MWT~ = 2.40 × 10^−9^) forming groups.

Protein Age, Functionality, and Killer Druggability Simultaneously Influence the Conservation of SET Proteins over NSET Group
-----------------------------------------------------------------------------------------------------------------------------

The time of origin of a protein strongly influences its rate of molecular evolution since protein cites some "memory" of its age ([@evw301-B53]). It has been found that younger proteins evolve faster than older proteins ([@evw301-B3]; [@evw301-B62]). Therefore, it is expected that SET proteins have to be comparatively older than NSET proteins. Using categorical gene age data of Domazet-Lošo and Tautz (2008), we found that younger proteins are significantly overrepresented in SET group than random expectation (odds ratio = 1.325, Z score = 2.233, *P* \< 2.55 × 10^−2^). Similar trend was observed when we carried another study with publicly available tool: "ProteinHistorian" ([@evw301-B8]) (average age~SET\ \[*n *=* *382\] ~≈ 949 Ma, average age~NSET\ \[*n *=* *1454\] ~≈ 1172 Ma, *P*~MWT~ = 4.00 × 10^−3^), although there exists an inverse correlation between protein age and evolutionary rates (~Age\ of\ proteins~ ρ ^*d*N ^= −0.364, *P* = 1.00 × 10^−6^, *n* = 1836). In view of the fact that tissue specific proteins are comparatively younger than housekeeping proteins ([@evw301-B18]; [@evw301-B64]; [@evw301-B61], [@evw301-B62]; [@evw301-B47]), we performed a correlation analysis between protein age and tissue expression breadth for our data set. A significant positive association between the variables (~Age\ of\ proteins~ ρ ^Expression\ breadth ^= 0.308, *P* = 1.00 × 10^−6^, *n* = 1409) strengthens the fact that lower tissue expression breadth of SET proteins are relatively younger than the NSET proteins. A comparison of protein age between SET and NSET proteins indicates a similar mode of age difference only within noncomplex forming group ([table 1](#evw301-T1){ref-type="table"}). All these results imply that the time of origin may have some influence to explain the evolutionary rate heterogeneity between SET and NSET proteins.Table 1Age Distribution of SET/NSET Proteins within Complex Forming and Noncomplex Forming GroupsResourceClassProteins Those Form Complex*P*-valueNoncomplex Forming proteins*P* valueProteinHistorian serverSET≈885 Ma1.82 × 10^−1^≈965 Ma1.10 × 10^−2\*\*^NSET≈1183 Ma≈1169 MaSupplementary MaterialOldSET: 14.69%5.50 × 10^−1^SET: 57.47%1.10 × 10^−3\*\*^NSET: 15.92%NSET: 63.31%NewSET: 4.64%6.38 × 10^−1^SET: 21.13%3.49 × 10^−2\*\*^NSET: 4.10%NSET: 13.71%[^2]

In an attempt to find the causes of target drug side effects, a recent article has highlighted that many of the drug side-effects stem from disruption of important biological processes/pathways ([@evw301-B39]). Therefore, one plausible reason of detecting variation in *d*N or *d*N/*d*S between SET and NSET proteins could be their differences in functionalities which strongly influence protein age as well as the rate of molecular evolution ([@evw301-B34]; [@evw301-B62]; [@evw301-B44]). Concentrating on biological functions (see "Materials and Methods" section) of proteins, we perceived that SET proteins are more multifunctional than NSET proteins (average pleiotropic index~SET\ \[*n *=* *387\] ~= 20.052, average pleiotropic index~NSET\ \[*n *=* *1480\]~ = 15.724, *P*~MWT~ = 3.57 × 10^−7^) where protein multifunctionality boosts its sequence conservation rates (~pleiotropic\ index~ ρ ^*d*N ^= −0.157, ~pleiotropic\ index~ ρ ^*d*N/*d*S ^= −0.155, *P* = 1.00 × 10^−6^, *n* = 1867). Here pleiotropic index has been used to measure the multifunctionality of a protein. Based on our result, we infer that multifunctionality could be a promising determinant of evolutionary rates of SET/NSET proteins. When we performed correlation analyses between protein biological functions, their age and killer druggability, we found that killer druggability increases with protein multifunctionality (~pleiotropic\ index~ ρ ^killer\ druggability*/*target* *^= 0.168, *P* = 1.00 × 10^−6^, *n* = 1867) and reduces with their age ([table 2](#evw301-T2){ref-type="table"}). Our result affirms that more multifunctional younger drug targets are candidates for acquiring killing side effects ([tables 2](#evw301-T2){ref-type="table"} and [3](#evw301-T3){ref-type="table"}). Furthermore, to interpret the impact of killer druggability on related biological parameters, we removed all SET proteins with killer druggability \> 0 \[55.41%; 215/388\] from our entire data set. We, thereby, noticed that the differences in protein age (considering numerical age data: SET = 1080 Mya, NSET = 1172 Mya, *P*~MWT~ = 3.33 × 10 ^−^ ^1^; considering categorical age data: SET *vs.* NSET old: 76.88% vs.79.23%, SET vs. NSET new: 22.54% vs.17.81%, *P *\> 5.00 × 10^−2^ in both cases) and protein multifunctionality (*P*~MWT~ = 3.33 × 10^−1^) no longer hold between SET and NSET groups. A consistent trend was obtained for noncomplex forming proteins where the *d*N difference exists for SET vs. NSET proteins (data not shown). From these observations, we conclude that higher killer druggability and multifunctionality have the potential to explain the lower evolutionary rates of recently emerged SET proteins over the NSET proteins. However, after removal of SET proteins with killer druggability \> 0, the average *d*N of SET proteins elevates from 0.062 to 0.066, although the between group (SET vs. NSET) *d*N difference (*P*~MWT~ = 1.90 × 10^−2^) still persists in rest of the data set. These findings corroborate that target killer druggability strongly influences protein age and functionality in the evolutionary landscape and partially explains the conservation of SET proteins over NSET group.Table 2Killer Druggability Per Target Proteins Using Age Data from Two Different ResourcesGene ClassKiller Druggability/Target (Considering age data of Domazet-Lošo and Tautz)Killer Druggability/Target (Considering Protein Historian server)New0.7150.421Old0.2100.248*P*~MWT~ value1.30 × 10^−4\*\*^3.60 × 10^−2\*\*^[^3]Table 3Comparison of Features between Drug Targets with Killing Side Effect(s) and with Nonkilling/No Side Effect(s)Serial no.GroupsEvolutionary Rates (dN)Pleiotropic IndexTissue Expression Breadth1Drug targeted proteins with killer druggability \> 00.05824.19572Drug targeted proteins with killer druggability = 000.08115.63612*P*~MWT~ value3.48 × 10^−4\*\*^5.94 × 10^−13\*\*^2.09 × 10^−8\*\*^[^4]

Impact of Protein Age and Sub-Cellular Localization for the Evolutionary Rate Difference of SET vs. NSET Proteins
-----------------------------------------------------------------------------------------------------------------

A significant evolutionary rate conservation of SET (*n *= 173) proteins with respect to NSET (*n *= 1488) group in rest of the data set (i.e. excluding drug targets with killing side effect \> 0) indicates that some other factor(s) also influence the evolutionary rates of SET (with no killing side effect) and NSET proteins. A significant difference (Wilcoxon rank sum test: *P* \< 2.20 × 10^−16^) in *d*N between randomized (10,000 simulated replicates) SET and NSET groups reassures that our result is insensitive to the nonuniform sample sizes of SET and NSET proteins. To determine the impact of gene age on *d*N in the data set of proteins exhibiting no killing side effects, we performed a correlation analysis between the two factors. A better correlation than whole data set (considering numerical age data: ~Age\ of\ proteins~ ρ ^*d*N ^= −0.390, *P* = 1.00 × 10^−6^, *n* = 1626) was observed by this way. When we compared the evolutionary rates of SET and NSET proteins separately within "old" and "new" age groups; the evolutionary rate variation was found only within new age group (considering both the age data resources; [fig. 3](#evw301-F3){ref-type="fig"}). So as the case for noncomplex forming young proteins (Data set of numerical age data; categorical age data respectively: *d*N~SET~ vs*. d*N~NSET~*P*~MWT~ = 1.00 × 10^−3^; *d*N~SET~ vs*. d*N~NSET~*P*~MWT~ = 6.00 × 10^−3^). Since because, the sample size distributions of SET and NSET proteins within new age class are statistically insignificant (Z = 1.524; *P *= 1.27 × 10^−1^); our observation confirms that protein age is a significant feature that drives SET/NSET protein evolutionary rates in new age group irrespective of sampling distribution.F[ig]{.smallcaps}. 3.---Comparisons of evolutionary rates (*d*N) of SET vs. NSET proteins within different age groups. In the figure, (*a*) the categorical age data are provided by Domazet-Lošo and Tautz (2008); (*b*) the numerical protein age data were obtained from ProteinHistorian ([@evw301-B8]). For numerical data, we considered proteins with age ≤ 500 Ma as "new" and rest as "old" proteins. The plots showing the importance of young/new gene age in the disparity of evolutionary rates of SET and NSET proteins. Error bars represent 95% confidence interval.

One possible reason for obtaining lower *d*N of SET proteins compared to the NSET proteins within the new age group could be their subcellular localization that largely imposes selective constraints on protein sequences in an order of intracellular *d*N/*d*S \< membrane *d*N/*d*S \< extracellular *d*N/*d*S ([@evw301-B33]; [@evw301-B58]). In this regard, it is already published that membrane-embedded proteins are of principal therapeutic interest due to the ease of drug binding to membrane proteins ([@evw301-B58]). Proceeding further, the proportions of membrane targets are found to be considerably higher in new SET proteins compared to the NSET proteins (considering ProteinHistorian ([@evw301-B8]) age data set: SET vs. NSET 18.02% vs*.* 6.95%, *Z* score = 5.030, *P\< *1.00 × 10 ^−^ ^4^; considering Domazet-Lošo and Tautz (2008) age data set: SET vs. NSET 10.46% vs*.* 4.22%, *Z* score = 3.588, *P *= 3.00 × 10^−4^). However, no such result was obtained for intracellular or extracellular target proteins (data not shown). When we estimated evolutionary rates of SET and NSET proteins within the new age class, *d*N of membrane localized SET proteins are found to be substantially lower than NSET proteins (average *d*N~SET\ *vs.*\ NSET ~= 0.0.086 vs*.* 0.162, average *d*N~SET\ *vs.*\ NSET~ = 0.093 vs*.* 0.182; considering numerical and categorical age data respectively; *P*~MWT\ \[SET\ *vs.*\ NSET\] ~\< 7.00 × 10^−3^ in both cases). Our results do not alter considering noncomplex new gene class ([table 4](#evw301-T4){ref-type="table"}). To understand why membrane located SET proteins evolve slower than NSET proteins, we considered transmembrane proteins (proteins containing transmembrane helices) because such proteins often demonstrate tissue restricted expression and evolve slowly due to their elevated buried residue composition ([@evw301-B43]; [@evw301-B49]; [@evw301-B4]). Thus, we noticed that only within new membrane protein class, transmembrane helices share a significant negative correlation to protein evolutionary rates (considering ProteinHistorian ([@evw301-B8]) data: ~Transmembrane\ helices/protein~ ρ ^*d*N ^= −0.367, *P* = 1.54 × 10^−5^, *n* = 132; considering Domazet-Lošo and Tautz (2008) age data: ~Transmembrane\ helices/protein~ ρ ^*d*N ^= −0.517, *P* = 1.04 × 10^−6^, *n* = 79). However, such correlation does not persist considering the whole data set (~Transmembrane\ helices/protein~ ρ ^*d*N ^= 0.032, *P* = 1.62 × 10^−1^, *n* = 1866) or considering data set after eliminating SET proteins with killing side effect(s) (~Transmembrane\ helices/protein~ ρ ^*d*N ^= 0.0.075, *P* = 2.00 × 10^−3^, *n* = 1652). It indicates that relatively higher number of transmembrane helices may be present in SET proteins within new membrane class in support of their lower evolutionary rates and this is the case in reality \[considering ProteinHistorian ([@evw301-B8]): average transmembrane helices~SET\ \[*n *=* *31\] ~= 4.742, average transmembrane helices~NSET\ \[*n *=* *101\]~ = 3.139, *P*~MWT~ = 3.00 × 10^−3^; considering Domazet-Lošo and Tautz (2008) age data: average transmembrane helices~SET\ \[*n *=* *18\] ~= 5.444, average transmembrane helices~NSET\ \[*n *=* *61\]~ = 3.361, *P*~MWT~ = 1.50 × 10^−3^\]. These results support the fact that simultaneous effect of protein age (young) and membrane localization of target are the driving force for distinct evolutionary rates of SET and NSET proteins.Table 4Distribution of SET/NSET Membrane Proteins within Complex Forming and Noncomplex Forming New Age Class Considering Targets with Killer Druggability = 0ResourceProteins Those Form Complex*Z* score, *P* valueNoncomplex Forming Proteins*Z* score, *P* valueAge data provided by Domazet-Lošo and TautzSET: 1.16%Z = 0.679,SET: 9.30%***Z* = 3.580**,NSET: 0.69%*P* = 4.97 × 10^−1^NSET: 3.54%***P* = 3.00 × 10^−4\*\*^**From age data of ProteinHistorian serverSET: 1.74%*Z* = 0.743,SET: 16.28%***Z* = 5.088**NSET: 1.10%*P* = 4.57 × 10^−1^NSET: 5.84%***P* \< 1.00 × 10^−4\*\*^**[^5]

Discussion
==========

In the present communication, we analyzed and compared the evolutionary rates of human drug side effect associated targets (SET) with respect to the targets having no available side effect data in the public repositories (NSET) to understand the biological features of targets contributing to drug side effect(s) in the evolutionary landscape. We observed that SET proteins evolve substantially slower than NSET proteins. To clarify the underlying reason of such fluctuations in evolutionary rates between SET and NSET proteins, we considered factors (gene expression levels, tissue expression breadth, target essentiality, total druggability, killer druggability, essential druggability of a target, complex association number, protein complex size, pleiotropic index, age of a protein, and protein subcellular localization) ([@evw301-B64]; [@evw301-B3]; [@evw301-B17]; [@evw301-B25]; [@evw301-B38]; [@evw301-B45]; [@evw301-B47]; [@evw301-B46]; [@evw301-B10]; [@evw301-B57], [@evw301-B58]; [@evw301-B4]; [@evw301-B63]) those either have known correlations or we conjectured to have relation with protein evolutionary rates. Thereby, we identified that noncomplex forming nature, time of origin of proteins, killer druggability of targets, multifunctionality, and subcellular localization play key roles to dictate the divergence in evolutionary rates between SET and NSET proteins among all other features.

To estimate protein evolutionary rates, we considered most common human-mouse orthologous pair due to the functional conservation between the two species in normal and pathological conditions ([@evw301-B38]; [@evw301-B7]; [@evw301-B22]). However, it is now established that a shorter generation time in the murid lineage may possess problems to estimate *d*N/*d*S ([@evw301-B28]). Moreover, it is well known that in human and mouse, *d*S is not constant and depends upon GC content, gene recombination rates, codon usage bias and several other parameters ([@evw301-B9]; [@evw301-B60]; [@evw301-B28]). Therefore, to avoid any confusion, a possible alternative is to consider another mammal to estimate *d*N, *d*S, and *d*N/*d*S. To serve the purpose, we used human-cow orthologous pair to compute evolutionary rates of SET (*n *= 375) vs. NSET (*n *= 1424) proteins. When we replicated the whole analyses between SET vs. NSET proteins using human-cow orthologous pair, we noticed that the results remain absolutely similar to what we found using human-mouse orthologs ([supplementary tables S1 and S2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Even, in the new data set, the *d*S value between two groups (*P*~MWT~ = 2.15 × 10^−1^) does not vary. This result suggests that the difference in *d*N/*d*S in SET vs. NSET proteins strongly depend on the nonsynonymous evolutionary distance, *d*N ([supplementary table S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) and our result is free from any bias due to orthology selection.

Previous study has affirmed the fact that the number of essential proteins that bind to a drug is a crucial factor of drug side effects rather than the total number of drugs that bind to a target ([@evw301-B57]). Regarding total druggability of a target, we draw a similar conclusion i.e. the evolutionary rates vary between SET and NSET groups independent of the total number of drug(s) against a target. Contemplating on essential targets, we noticed that the rates of molecular evolution do not vary between SET and NSET proteins, even though essential proteins are significantly overrepresented in SET group. Since, essential proteins are multifunctional in nature ([@evw301-B10]; [@evw301-B2]); one plausible reason for not obtaining such evolutionary rate difference could be due to the equal number of biological process involvement (*P*~MWT~ = 1.11 × 10^−1^) of SET and NSET proteins in the essential group. Introducing essential druggability of a target, we detected slow evolutionary rates for proteins with higher essential druggability compared to proteins with lower essential druggability. Again, proteins are pooled into three bins according to their essential target druggability (bin 1 \[number: 1--2\]: Low, bin 2 \[number: 3--4\]: Medium, bin 3 \[number ≥5\]: High). No difference in *d*N even where variation in essential druggability exists (in bin 1 and bin 3; see "Results" section) suggests that the evolutionary rate heterogeneity between SET and NSET proteins does not solely rely on target essential druggability. In this context, it is well known that disruption/alteration of a biological function often lead to the progression of human diseases which are overrepresented in targets with elevated drug side effects ([@evw301-B31]; [@evw301-B4]). When we estimated protein functionality in three bins (showing no difference in *d*N), we did not find any difference in protein functionality between SET and NSET groups within those bins (bin 1: *P*~MWT~ = 7.64 × 10^−1^, bin 2: *P*~MWT~ = 8.23 × 10^−1^, bin 3: *P*~MWT~ = 5.70 × 10^−1^). This study indicates that protein functionality, rather than protein essentiality or essential target druggability, is one of the key evolutionary rate determinants of SET and NSET proteins in the evolutionary landscape.

In our study, we found that within noncomplex forming group, SET and NSET proteins are under distinct selective constraints. However, within complex forming group, such evolutionary rate difference does not persist. One plausible reason might be essential proteins are largely involved in protein complexes to execute important biological functions ([@evw301-B11]; [@evw301-B50]). Since, we did not notice any difference in the evolutionary rates and functionalities of SET and NSET proteins within the essential group; it could be a reason for not obtaining complex number variation between SET and NSET proteins. In this context, we know that disturbed essential genes may impact all the genes in an organism by causing complete cell death and therefore, majority of human disease genes are nonessential in nature ([@evw301-B23]; [@evw301-B24]). We have previously seen that human disease genes are largely associated with drug side effects ([@evw301-B4]). Therefore, in agreement to [@evw301-B23], we here confirm that nonessential noncomplex forming proteins are the major candidates of drug side effects and influence the evolutionary trajectory of SET and NSET proteins.

Disruption of cell division and expression regulation can also lead to drug side effects in many cases ([@evw301-B39]). Thus, indispensable factors of protein evolutionary rates are expression level of a gene as well as tissue expression breadth ([@evw301-B17]; [@evw301-B47]). However, in contrast to our expectation, in both cases we noticed that conserved SET proteins are lowly expressed as well as tissue restricted in nature compared to NSET proteins. It may be due to the fact that restricted expression of SET proteins ([table 3](#evw301-T3){ref-type="table"}) may impede the spread of drug side effects (especially killing side effects) along the links of the interactome network to maintain the activity of their interaction partners and undergo reasonable purifying selection to keep the side effects restricted in a limited number of tissues. However, from evolutionary perspective, our results suggest that gene expression levels or tissue expression breadth alone is inadequate to explain the evolutionary rate difference between SET and NSET proteins.

Previous communications have claimed that phylogenetic age of a protein strongly influences the rates of protein evolution ([@evw301-B3]; [@evw301-B62]). Even though, SET proteins are highly conserved in nature, such proteins are found to be substantially younger than NSET proteins. Contrary to the previous findings i.e. ancient/old proteins are more multifunctional ([@evw301-B62]); we obtained a higher multifunctionality of druggable young proteins than ancient proteins. It is also found that such multifunctional young SET proteins are candidates those acquire undesirable killing side effects. Thus, higher killer druggability and multifunctionality supports the lower evolutionary rates of SET proteins over the NSET proteins. However, killer druggability cannot be a sole attribute to explain the discrepancy in evolutionary rates between SET and NSET proteins, since it is a characteristic of SET proteins. For better understanding, SET proteins with killing side effects were eliminated from our data set. We, thereby, found that membrane-embedded young transmembrane proteins significantly explain the evolutionary rate diversity between SET and NSET proteins.

Potential Caveat
----------------

The purpose of our study is to detect genomic and structural evolutionary features those can help to capture the general properties of side effect associated targets and in turn, may help to predict SET or NSET proteins based on the characteristic features employed in our analyses. Experimental validation of our outcome is time-consuming and therefore, the scope is quite limited. One potential caveat of our study is the incomplete set of experimental side effect data of SIDER v.2 ([@evw301-B36]) database which plausibly may introduce some bias in our results. To address the problem, we thought of revalidating our analyses with some experimental/manually curated side-effect databases of human. However, due to lack of experimental side-effect database apart from SIDER ([@evw301-B36]), we focused to use advanced version of SIDER (v.4.1) database to revalidate our analyses. In contrast to SIDER v.2, we identified 48 proteins whose annotations differ from the previous version (i.e. SET in the current data set which used to be NSET in SIDER2 and vice versa) and the SET protein number increased from 388 to 414 using the newer version (v.4.1) SIDER ([supplementary table S2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} Online). Replicating the whole analyses with the newer data set of SET (*n *= 414) and NSET (*n *= 1462) proteins reflected similar trends of results (data not shown) as previously obtained, although the magnitudes differed. Such observation reconfirms the fact that our evolutionary rate parameters can be used further to predict unknown SET/NSET proteins in human.

SVM Training and Prediction of SET/NSET Proteins
------------------------------------------------

To understand the influences of all the 13 evolutionary rate attributes (*d*N, *d*N/*d*S, gene expression level, tissue expression breadth, protein age, complex/noncomplex forming ability, functionality, subcellular localization, number of transmembrane helices, target total druggability, target essentiality, target essential druggability, and target killer druggability) those showing significant difference between SET and NSET proteins, we trained two mathematical SVM models (using gene age data from two different resources---model 1 incorporates categorical gene age data of Domazet-Lošo and Tautz (2008) and model 2 uses numerical gene age data of ProteinHistorian server ([@evw301-B8])) with these parameters and optimized the kernel parameters C and γ to maximize the prediction accuracy as well as the MCC value of our model. Since, SVM uses numerical values of predictors; we assigned +1 and −1 value to the categorical predictors before scaling and training the model. A predictor which is unable to predict one class (small TP or TN) adequately is undoubtedly biased and less informative, and in such cases MCC can critically assess the bias of a result by acquiring a negative or nearly zero value ([@evw301-B14]; [@evw301-B35]). We found that the optimal values of C and γ for our SVM models are 32 and 0.0078125, respectively. When we trained our models using these kernel parameters and applied on test sets to predict SET/NSET proteins, we observed that the success rate (∼86%) and all other performance measures for both the models ([table 5](#evw301-T5){ref-type="table"}) are quite impressive. When we excluded *d*N/*d*S attribute from our analyses, the optimal values of C and γ become 1 and 0.0078125, respectively. In that case, the success rates decrease by ∼5% (accuracy of model 1 and model 2 are 80.92% and 81.29%, respectively) for both of our SVM models. Furthermore, this study reveals that using *d*N and *d*N/*d*S altogether have the potential to increase the prediction accuracy of our models.Table 5Efficiency Evaluation of Our Optimized SVM ModelTest SetMCCSensitivitySpecificityPPVNPV*F*-measureOur data set using categorical gene age data[^a^](#evw301-TF5){ref-type="table-fn"}0.481029.26%99.74%94.94%85.30%44.57%Our data set using numerical gene age data[^a^](#evw301-TF5){ref-type="table-fn"}0.505631.47%99.75%97.02%85.11%47.39%[^6]

In addition, we optimized the kernel parameters C and γ of our SVM models trained with all 13 evolutionary rate parameters using 5-fold cross-validation. In such a case, our data set was broken into five subsets: (i) four subsets are used to train the classifier and (ii) rest of the subset is used as a test set to evaluate prediction accuracy using the trained model ([@evw301-B14]). The process is replicated five times so that all subsets could be used for training and testing ([@evw301-B14]). The prediction accuracy achieved by this process remains almost similar to what we found before (cross validation accuracy of model 1 is 86.03% and the accuracy of model 2 is 85.98%).

DR. PRODIS, a recent open access web server, has been designed to identify side effect associated proteins in the human genome with a reported precision of ∼57% and a recall of ∼24% ([@evw301-B65]). We mapped the annotations (SET/NSET) of DR. PRODIS to our data set of 1876 proteins to compare the performances of our SVM models with respect to DR. PRODIS web server. Drug side effect associated targets provided by the SIDER v.2 database ([@evw301-B36]) was used to benchmark the approach. We, thereby, noticed that our optimized SVM models outperform DR. PRODIS server in terms of MCC, accuracy, specificity, PPV, NPV, and F-measure, respectively, except for sensitivity measure. In contrast to the performance of our models as summarized in [table 5](#evw301-T5){ref-type="table"}, the MCC, accuracy, specificity, PPV, NPV, and F-measure of DR. PRODIS for the 1876 human proteins are −0.1056, 49.09%, 53.02%, 15.88%, 75.50%, and 21.66%, respectively. However, the sensitivity for our models are in the range of ∼29% to 31.5% which is almost comparable to the sensitivity of DR. PRODIS (i.e. 34.02%) for our data set. Based on the MCC value, we infer that our models predict better than the previous existing prediction server. Even when we used human-cow orthologs, we achieved a prediction success rate of ∼80% (for model 1 and model 2 prediction accuracy are 79.58% and 80.74%, respectively) using all 13 evolutionary rate attributes. Comparison of our prediction results in terms of MCC (model 1 and model 2 MCC are 0.2203 and 0.2259 respectively) to the results of DR. PRODIS further strengthens our conclusion that our prediction models work better than the existing prediction model irrespective of our orthology selection.

Concluding Remarks
------------------

To conclude, our systematic study reports the key factors leading to drug side effects in the framework of protein evolution. It is clear from this communication that the evolutionary origin, involvement in biological processes, noncomplex forming ability and localization of targets are the special features for predicting candidates with drug (killing) side effects. Our study has described the relative influences of killer druggability vs. essential druggability on protein evolutionary rates considering nonside effect associated (NSET) proteins as control. Furthermore, our results help to identify unknown SET/NSET proteins in human. Using all 13 evolutionary rate attributes incorporated in this study, our SVM models perform predictions that are much better than the existing prediction server. With the increasing coverage of the drug side effect associated data in human, more interesting analyses can be performed to further dissect the properties of drug targets and the associated side effects and the accuracy of our prediction models can be further improved.

Supplementary Material
======================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at *Genome Biology and Evolution* online.
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[^2]: N[ote]{.smallcaps}.---Significant difference \*\*(*P*\< 0.05) between pairs are highlighted in bold. Mann--Whitney U test was used to demonstrate the difference in protein numerical age data taken from ProteinHistorian.
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